Pancreatic Cancer Canada ’s Post

Personally motivated by his own family experience with cancer, Dr. Eugene Koay has dedicated his career to unravelling some of the mysteries of pancreatic cancer. Dr. Koay, Professor of GI Radiation Oncology at The University of Texas MD Anderson Cancer Center is the lead researcher on an innovative study funded by Pancreatic Cancer North America that is harnessing artificial intelligence for the early detection of pancreatic cancer. “What excites me about this research is the opportunity to make real progress against a very deadly disease. It’s also thrilling to work at the cutting edge, as no other research currently combines this specific set of biomarkers with medical imaging. For the first time, we’ll be able to explore how these tools and technologies can improve outcomes for patients at risk.” Learn more about this cutting-edge research and how it could dramatically change survival rates for pancreatic cancer by advancing our knowledge about early detection: https://lnkd.in/giJNU9K5 #pancreaticcancerawarenessmonth #survivalnotsympathy #pancreaticcancer #cancerresearch

Exciting Updates from CBmed's research project on #liquidbiopsy in cancer! We’re thrilled to share some recent milestones from our collaboration with the Medizinische Universität Graz and QIAGEN: ✨ Last week, Prof. Amin El-Heliebi and 𝐌𝐚𝐫𝐠𝐚𝐫𝐞𝐭 𝐙𝐢𝐧𝐧𝐞𝐠𝐞𝐫 represented our project at the prestigious European Association for Cancer Research (EACR) 𝐋𝐢𝐪𝐮𝐢𝐝 𝐁𝐢𝐨𝐩𝐬𝐢𝐞𝐬 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 in Lyon. Prof. El-Heliebi not only submitted a poster abstract but was also selected for a 𝐬𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧, highlighting our innovative work in liquid biopsy research. 📄 Our groundbreaking research has reached another milestone with the publication of a new paper: “𝑨𝒅𝒗𝒂𝒏𝒄𝒆𝒅 𝒔𝒊𝒏𝒈𝒍𝒆-𝒄𝒆𝒍𝒍 𝒂𝒏𝒅 𝒔𝒑𝒂𝒕𝒊𝒂𝒍 𝒂𝒏𝒂𝒍𝒚𝒔𝒊𝒔 𝒘𝒊𝒕𝒉 𝒉𝒊𝒈𝒉-𝒎𝒖𝒍𝒕𝒊𝒑𝒍𝒆𝒙 𝒄𝒉𝒂𝒓𝒂𝒄𝒕𝒆𝒓𝒊𝒛𝒂𝒕𝒊𝒐𝒏 𝒐𝒇 𝒄𝒊𝒓𝒄𝒖𝒍𝒂𝒕𝒊𝒏𝒈 𝒕𝒖𝒎𝒐𝒓 𝒄𝒆𝒍𝒍𝒔 𝒂𝒏𝒅 𝒕𝒖𝒎𝒐𝒓 𝒕𝒊𝒔𝒔𝒖𝒆 𝒊𝒏 𝒑𝒓𝒐𝒔𝒕𝒂𝒕𝒆 𝒄𝒂𝒏𝒄𝒆𝒓: 𝑼𝒏𝒗𝒆𝒊𝒍𝒊𝒏𝒈 𝒓𝒆𝒔𝒊𝒔𝒕𝒂𝒏𝒄𝒆 𝒎𝒆𝒄𝒉𝒂𝒏𝒊𝒔𝒎𝒔 𝒘𝒊𝒕𝒉 𝒕𝒉𝒆 𝑪𝒐𝑫𝒖𝑪𝒐 𝒊𝒏 𝒔𝒊𝒕𝒖 𝒂𝒔𝒔𝒂𝒚” by Bonstingl et al. You can read it here: 👉https://lnkd.in/dVpXp4xj We are incredibly proud of the team and grateful for our partners as we continue pushing the boundaries of cancer research. 💡 Stay tuned for more updates on our journey to advance personalized medicine through liquid biopsy innovation! #CBmed #MedicalUniversityGraz #Qiagen #liquidbiopsy #cancerresearch #EACR #precisionmedicine #biomarkerresearch

Cancer research breakthrough! Researchers at WEHI (Walter and Eliza Hall Institute of Medical Research) have discovered a groundbreaking two-in-one immunotherapy that targets aggressive brain cancer, glioma, while also boosting the immune system to develop a lasting defence against it. This innovative CAR T cell therapy not only eliminates cancer cells but also strengthens the body's defence against future tumours. With the potential to transform treatment options for patients, this discovery could mean longer survival times and improved quality of life. “The possibility of providing patients with a long-lasting immune response against their cancer is a game-changer, offering a significantly better outlook for patients and their families,” Professor Jenkins, Lead researcher and laboratory head at WEHI. Learn more about this promising research and its impact for the future of brain cancer treatment: https://bit.ly/4f8anwe #cancerresearch #backingbrilliant

🍍 Dr. Minesh Mehta: A Lifetime Leader in Brain Metastasis Research 🌟 From humble beginnings in a remote Ugandan village to becoming one of the most prolific and cited authors in brain metastasis research, Minesh Mehta, M.D., deputy director, chief of radiation oncology at Miami Cancer Institute and John and Mary Lou Dasburg Endowed Chair in Radiation Oncology is transforming care for some of the most complex cancer cases. Dr. Mehta’s groundbreaking work includes: 🔬 Advancing #protontherapy to improve precision and reduce side effects. 🧠 Leading international studies like the METIS trial, which doubled time to intracranial progression for #NSCLC patients. 🧪 Pioneering the ADORATION trial, combining Azeliragon and stereotactic radiosurgery to combat metastatic brain cancer. 💡Learn more about Dr. Mehta’s remarkable contributions and his journey to advancing brain cancer treatments 👉 https://bapth.lt/BMMehta #BrainMetastasis #BrainCancer #RadOnc

Pink October: Together for Breast Cancer Awareness! This month, we unite to raise awareness for Pink October, an international campaign dedicated to increasing understanding, early detection, and support for breast cancer. 💖 As the Principal Investigator of the IMPACT project, our research group at the University of Malta is deeply engaged in breast cancer research. The Laboratory of Molecular Oncology (Department of Pathology) is proud to have contributed to the field with 4 PhD graduates who focused on novel biomarkers, disease mechanisms, therapy resistance, and disease heterogeneity. Currently, 2 PhD candidates are working on tumour invasion and novel isoforms linked to aggressive breast cancer. Cancer research is a challenging yet essential endeavour, and we remain committed to making a difference in the fight against breast cancer. #PinkOctober #BreastCancerAwareness #BreastCancerResearch #IMPACTProject #CancerResearch #EarlyDetection #TogetherWeFight #SupportTheCause #PhDResearch #InnovationInHealthcare

Pink October: Together for Breast Cancer Awareness! This month, we unite to raise awareness for Pink October, an international campaign dedicated to increasing understanding, early detection, and support for breast cancer. 💖 As the Principal Investigator of the IMPACT project, our research group at the University of Malta is deeply engaged in breast cancer research. The Laboratory of Molecular Oncology (Department of Pathology) is proud to have contributed to the field with 4 PhD graduates who focused on novel biomarkers, disease mechanisms, therapy resistance, and disease heterogeneity. Currently, 2 PhD candidates are working on tumour invasion and novel isoforms linked to aggressive breast cancer. Cancer research is a challenging yet essential endeavour, and we remain committed to making a difference in the fight against breast cancer. #PinkOctober #BreastCancerAwareness #BreastCancerResearch #IMPACTProject #CancerResearch #EarlyDetection #TogetherWeFight #SupportTheCause #PhDResearch #InnovationInHealthcare

Micro-C in Cancer Research: MacroH2A Influences in the Melanoma Tumor Microenvironment A recent study in Nature Cell Biology by Dan Filipescu and his team at the Icahn School of Medicine at Mount Sinai, has uncovered the critical role of the histone variant macroH2A in melanoma. Their research shows how the absence of macroH2A influences the tumor microenvironment, leading to larger tumors and a suppressed immune response. Utilization of Dovetail’s Micro-C kit helped enable new possibilities for developing treatments that enhance the body’s natural defenses against cancer. As research continues, these findings bring hope for more effective and targeted therapies for melanoma and potentially other cancers. Read our blog here:https://lnkd.in/gQrz4R8b Full Publication: https://lnkd.in/g2Ufgbjm #CancerResearch #Melanoma #TumorMicroenvironment #HistoneVariant #MacroH2A #Immunotherapy #ScientificBreakthrough

I’m thrilled our paper about a novel CAR therapy treating human solid cancers is out today in Science Advances. Kudos to MD-PhD student Christopher Nishimura and all co-authors!! During the past seven years, we have developed a new CAR:  TMIGD2 optimized potent/persistent (TOP) CAR. Compared to the second and third generation CAR with CD28-4-1BB as costimulatory domains, our TOP CAR showed superior anti-tumor activity, survival/expansion/persistence, CD8/CD4 T cell ratio, mitochondrial metabolism, and generated less cytokines and exhaustion. Our TOP CAR is a new platform to treat various human solid cancers. As the first example in this paper, we used TOP CAR-T targeting B7-H3 (CD276) in in vivo orthotopic models of human pancreatic cancer, glioblastoma, and lung cancer. Einstein has intellectual property protection with three pending patents for this novel technology,  and is seeking commercial partners to move this novel TOP CAR therapy into clinical trials in the near future, including for cancer of the brain, liver, pancreas, ovary, prostate, lung, bladder, colon, and others. Paper PDF: TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors: https://lnkd.in/e-47t2X9

Lung cancer remains the leading cause of cancer-related deaths worldwide, but Dr. Sarah Yeo and the TRACKER team are driving critical progress in research. At the Thoracic Oncology Group of Australasia ASM2024, clinician and Olivia Newton-John Cancer Research Institute PhD student Dr. Yeo shared pioneering work on a national biobanking initiative focused on advanced lung cancer. 🌍✨ With 76 patients already recruited, they're using cutting-edge EBUS (ultrasound-guided) sampling to uncover new insights into metastatic lung cancer and overcome immunotherapy resistance. Together, they’re paving the way for breakthroughs in identifying markers of treatment response and developing more effective therapies. 💡🙌 #TOGA2024 #LungCancer #Research #Immunotherapy #EBUS #Biobanking #ONJCRI #AntiCancer #Conference #Presentation

Micro-C in Cancer Research: MacroH2A Influences in the Melanoma Tumor Microenvironment A recent study in Nature Cell Biology by Dan Filipescu and his team at the Icahn School of Medicine at Mount Sinai, has uncovered the critical role of the histone variant macroH2A in melanoma. Their research shows how the absence of macroH2A influences the tumor microenvironment, leading to larger tumors and a suppressed immune response. Utilization of Dovetail’s Micro-C kit helped enable new possibilities for developing treatments that enhance the body’s natural defenses against cancer. As research continues, these findings bring hope for more effective and targeted therapies for melanoma and potentially other cancers. Read our blog here:https://lnkd.in/gQrz4R8b Full Publication: https://lnkd.in/g2Ufgbjm #CancerResearch #Melanoma #TumorMicroenvironment #HistoneVariant #MacroH2A #Immunotherapy #ScientificBreakthrough